Intellia Appoints Perry Karsen As Chairman Of Its Board Of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and most recently, Chief Executive Officer of Celgene’s cellular therapeutics division. Previously, Mr. Karsen was President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca.
Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and most recently, Chief Executive Officer of Celgene’s cellular therapeutics division. Previously, Mr. Karsen was President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca.